Twenty years of development in fertility preservation of women and girls and the challenges that remain

Rodriguez‐Wallberg, Kenny A.; Gemzell‐Danielsson, Kristina

doi:10.1111/aogs.13615

Cited by 5 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For female patients, methods such as the cryopreservation of oocytes, embryos, or ovarian tissue may be offered [1,3,4,5,6]. The development of techniques for fertility preservation has rapidly evolved into a fruitful research field with a focus not only on patients of reproductive age, but also on children and adolescents [7], and programs for fertility preservation have been established in many countries and have reported a continuous increase in numbers of patients undergoing such procedures [8,9,10,11,12]. However, female fertility preservation options are challenging in several clinical situations, such as the case of pre-pubertal girls in whom mature oocyte cryopreservation is not feasible or when time constraints do not allow for hormonal stimulation aiming at mature egg retrieval in adult women.…”

Section: Introductionmentioning

confidence: 99%

Ovarian Follicle Depletion Induced by Chemotherapy and the Investigational Stages of Potential Fertility-Protective Treatments—A Review

Hao

Anastácio

Liu

et al. 2019

IJMS

View full text Add to dashboard Cite

Ovarian follicle pool depletion, infertility, and premature menopause are all known sequelae of cancer treatment that negatively impact the quality of life of young cancer survivors. The mechanisms involved in this undesired iatrogenic ovarian damage have been intensively studied, but many of them remain unclear. Several chemotherapeutic drugs have been shown to induce direct and indirect DNA-damage and/or cellular stress, which are often followed by apoptosis and/or autophagy. Damage to the ovarian micro-vessel network induced by chemotherapeutic agents also seems to contribute to ovarian dysfunction. Another proposed mechanism behind ovarian follicle pool depletion is the overactivation of primordial follicles from the quiescent pool; however, current experimental data are inconsistent regarding these effects. There is great interest in characterizing the mechanisms involved in ovarian damage because this might lead to the identification of potentially protective substances as possible future therapeutics. Research in this field is still at an experimental stage, and further investigations are needed to develop effective and individualized treatments for clinical application. This review provides an overview of the current knowledge and the proposed hypothesis behind chemotherapy-induced ovarian damage, as well as current knowledge on possible co-treatments that might protect the ovary and the follicles from such damages.

show abstract

Section: Introductionmentioning

confidence: 99%

Ovarian Follicle Depletion Induced by Chemotherapy and the Investigational Stages of Potential Fertility-Protective Treatments—A Review

Hao

Anastácio

Liu

et al. 2019

IJMS

View full text Add to dashboard Cite

show abstract

“…Commonly used alkylating drugs, such as cyclophosphamide (CPA), are highly gonadotoxic and a significant proportion of female cancer survivors develop premature ovarian failure and subsequent infertility [2,3]. In clinical medicine, options for fertility preservation have been developed and an increasing demand for fertility preservation procedures has been reported [4], with a growing number of research reports Int. J. Mol.…”

Section: Introductionmentioning

confidence: 99%

Ovarian Follicles Rescued 3 Days after Cyclophosphamide Treatment in Adolescent Mice: An Experimental Study Aiming at Maximizing Methods for Fertility Preservation through In Vitro Follicle Culture

Anastácio

Waterstone

Hao

et al. 2019

IJMS

Self Cite

View full text Add to dashboard Cite

There is currently a lack of knowledge about the feasibility of performing procedures for fertility preservation after chemotherapy treatment has been initiated. In this experimental controlled study using adolescent mice, we aimed to investigate if the chance of rescuing and growing in vitro secondary follicles (SeF) would be affected three days after a single injection of cyclophosphamide (CPA). The main outcomes included were: (1) The number of SeF with good morphologic quality obtained per ovary 3 days after CPA injection, (2) SeF development in culture, (3) small follicle density (SFD) on histology, and (4) apoptosis markers, including terminal deoxynucleotidyl transferase dUTP nick end-labelling (TUNEL), mRNA expression, and distribution of p 53 upregulated modulator of apoptosis (Puma) and phosphatase and tensin homolog (Pten). We found a 60% reduction of SeF obtained per ovary in all CPA-treated groups vs. controls. However, in vitro survival rates at culture day 12 and antrum formation were similar among all groups. On histology, SFD was only significantly reduced in the high CPA dose group. Apoptotic cells were mainly found in large growing follicles of CPA groups. Our study indicates the feasibility of SeF isolation and in vitro follicle culture 3 days following CPA treatment and a still preserved SFD, particularly following a low-dose CPA treatment.

show abstract

Fertility and Sexuality in Cancer Survivors

Condorelli

Goldrat

Demeestere

2021

Survivorship Care for Cancer Patients

View full text Add to dashboard Cite

Twenty years of development in fertility preservation of women and girls and the challenges that remain

Cited by 5 publications

References 10 publications

Ovarian Follicle Depletion Induced by Chemotherapy and the Investigational Stages of Potential Fertility-Protective Treatments—A Review

Ovarian Follicle Depletion Induced by Chemotherapy and the Investigational Stages of Potential Fertility-Protective Treatments—A Review

Ovarian Follicles Rescued 3 Days after Cyclophosphamide Treatment in Adolescent Mice: An Experimental Study Aiming at Maximizing Methods for Fertility Preservation through In Vitro Follicle Culture

Fertility and Sexuality in Cancer Survivors

Contact Info

Product

Resources

About